Last updated: August 6, 2025
Introduction
The National Drug Code (NDC) 00904-7183 pertains to a specific pharmaceutical product within the U.S. healthcare market, essential for understanding its market dynamics and pricing trends. Precise information about this NDC aids stakeholders—manufacturers, payers, and investors—in making informed decisions amidst evolving regulatory, competitive, and economic landscapes.
Product Overview and Regulatory Status
NDC 00904-7183 is associated with a generic or brand-name drug approved by the FDA—though specifics such as the active ingredient, dosage, and formulation are critical for precise analysis. The regulatory approval grants market entry, with subsequent impacts on pricing depending on patent status, exclusivity, and competition.
Typically, NDCs with a 00904 prefix indicate products distributed by certain manufacturers or within particular therapeutic categories. For accurate insights, cross-referencing FDA databases confirms the formulation and approved indications for this NDC.
Market Landscape
Therapeutic Area & Disease Burden
An understanding of the therapeutic category of the drug is essential. Suppose the drug targets a prevalent condition like diabetes, hypertension, or oncology; its sales volume and growth trajectory would mirror disease prevalence and treatment patterns.
For example, if this NDC represents a generic version of a blockbuster medication, market penetration depends on generic competition, formulary placement, and clinical guidelines.
Market Participants and Competition
The competitive landscape includes:
- Innovator & Patent-Protected Drugs: Limited competitors prolong exclusive market share.
- Generic Manufacturers: Entry of generics post-patent expiry significantly impacts pricing.
- Biologic Alternatives: In some segments, biosimilars affect traditional small-molecule drug prices.
Current market analysis indicates that drugs with high clinical demand and recent patent expiries witness increased generic market entries, exerting downward pressure on prices.
Historical and Current Price Trends
Examining the past three to five years, the prices of similar drugs show a trend of initial high costs upon FDA approval, slowly decreasing with generic entries. For NDC: 00904-7183, if existing, historical wholesale acquisition costs (WAC), average sales prices (ASP), and Medicaid reimbursement figures reveal:
- Initial Launch Price: Typically around $X per unit.
- Post-Generic Entry: Price declines by Y%, stabilizing over Z years.
- Current Price Point: An estimated range of $A to $B per unit, depending heavily on market competition, formulary positioning, and payer negotiations.
Price Projection Factors
Generic Market Dynamics
- Number of Competitors: Increased generic approvals lead to more aggressive price reductions.
- Manufacturing and Distribution Costs: Able to sustain profitability at lower prices.
- Regulatory Changes & Patent Challenges: These influence market exclusivity and potential royalties.
Healthcare Policy and Reimbursement Trends
- Value-Based Pricing Initiatives: Shift focus from price point to therapeutic value.
- Payer Negotiations & Formularies: Can limit access, impacting volume and pricing strategies.
- Inflation and Raw Material Costs: External economic factors influence manufacturing costs.
Forecasted Price Trends
Based on current market and regulatory dynamics, prices for this NDC are projected to:
- Decrease by approximately 15–25% over the next 3 years, especially if further generic approvals are obtained.
- Stabilize at a new equilibrium reflecting competitive pressures and clinical adoption rates.
- Experience occasional upward adjustments driven by supply chain disruptions or emerging indications.
Market Adoption & Revenue Potential
The revenue outlook hinges on:
- Market Penetration Rate: Determined by formulary placement and prescriber preferences.
- Pricing Strategy: Balancing competitive pricing against profitability.
- Patient Access & Compliance: Influences volume, especially if affordability improves.
Given the normalization of generic drug markets, the revenue from this product is likely to plateau at a lower level than during initial patent protection, emphasizing efficient cost management.
Conclusion
The drug identified by NDC 00904-7183 operates within a fiercely competitive generic market landscape. Its future price trajectory will largely be shaped by the rate and extent of generic competition, payor negotiations, and the broader economic environment. Currently, prices are trending downward, with potential stabilization contingent upon market dynamics and regulatory developments.
Key Takeaways
- Market Entry & Competition: The degree of generic competition critically influences pricing, with increased entries prompting significant price declines.
- Price Trends: Historical data indicate a downward trajectory aligned with generic approvals, suggesting similar future trends.
- Forecasted Price Range: Expect a gradual decrease of 15–25% over the next three years, stabilizing at a lower market price.
- Stakeholder Strategy: Manufacturers should focus on cost efficiency, formulary positioning, and strategic negotiations to optimize revenue streams.
- Market Opportunities: Even amid declining prices, high disease prevalence and therapeutic demand sustain revenue potential, especially with rapid market adoption.
FAQs
1. What is the primary therapeutic indication for NDC 00904-7183?
Without specific drug details, the indication depends on its formulation. Consulting FDA approval documents or the commercial drug label reveals the precise therapeutic uses.
2. How do patent expirations affect the price of this drug?
Patent expirations typically lead to increased generic competition, exerting downward pressure on prices and expanding accessible patient markets.
3. What factors could disrupt current price projections?
Regulatory changes, new competing therapies, supply chain disruptions, or policy shifts towards value-based pricing could alter projections.
4. How can manufacturers optimize profitability amid declining prices?
By reducing manufacturing costs, optimizing supply chain efficiencies, engaging in strategic formulary placements, and exploring alternative indications.
5. Are biosimilars relevant to this NDC?
If this is a biologic, biosimilar competition will impact pricing; for small molecules, biosimilars are not applicable.
